Investing.com -- Sarepta Therapeutics shares plunged premarket on Friday after the company disclosed another patient death ...

Interactive Brokers reported quarterly earnings of 51 cents per share, which beat the analyst consensus estimate of 45 cents.

Shares of Sarepta Therapeutics declined 16.5% in premarket trading on Friday after a Bloomberg report that a trial patient who received an experimental gene therapy has died from liver failure, making ...